Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. bacdrug

BacDrug SIGNED

Bacterial membrane vesicles a novel delivery system for the treatment of multi-drug resistant Gram-negative bacterial infections.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BacDrug project word cloud

Explore the words cloud of the BacDrug project. It provides you a very rough idea of what is the project "BacDrug" about.

resistance    shortage    faculty    toxic    negative    provides    tackle    exploited    indispensable    themselves    lactococcus    frequent    payload    harness    health    outcome    therapeutic    outer    cargo    selective    treatments    infections    strategies    acute    human    environment    nanotechnology    fellowship    molecular    caused    kill    world    prof    combat    strategy    groups    gram    innovative    treatment    placed    delivering    vesicles    pass    led    combined    collaborative    mortality    diseases    pathogenic    engineering    resistant    icl    nanocarriers    biology    microbiology    spread    global    dearth    andrew    setting    truly    bacdrug    prevention    stevens    consequently    highest    maximise    bioengineering    public    globally    clinics    bacteria    drug    load    antibiotics    edwards    lactis    combines    protect    expertise    clinical    alarming    burden    dr    class    successful    pathogens    bacterial    techniques    bmvs    drugs    membrane    translational    organization    alternative    urgent    molly    coupled    lipid    interdisciplinary    genetic    training    cross    chemical    materials   

Project "BacDrug" data sheet

The following table provides information about the project.

Coordinator		 IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Total cost 212˙933 €
 EC max contribution 212˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 212˙933.00

Map

 Project objective

'Bacterial infections are a significant public health challenge and a major cause of human mortality globally. Antibiotics are indispensable for the treatment and prevention of infections caused by bacteria. However, global spread of drug-resistant bacteria, coupled with a dearth of new antibiotics in development has led to an alarming shortage of effective drugs. Gram-negative bacteria, in particular, protect themselves against antibiotics with a highly selective outer membrane. The high burden of diseases caused by Gram-negative bacteria, combined with their frequent multi-drug resistance has placed them as world´s highest-priority pathogens by the World Health Organization. Consequently, there is an urgent need for novel therapeutic approaches that combat Gram-negative bacterial pathogens. The goal of 'BacDrug' is to use lipid-based bacterial membrane vesicles (BMVs) produced by non-pathogenic Lactococcus lactis as delivery system. BMVs have great potential as nanocarriers to by-pass the outer membrane and deliver their toxic payload to kill drug-resistant Gram-negative pathogens. A range of strategies will be used to load BMVs with cargo, including genetic engineering of L. lactis as well as chemical treatments. This Fellowship will harness expertise and techniques across microbiology, molecular biology, nanotechnology and drug design to deliver a successful outcome. The collaborative, truly interdisciplinary, cross faculty setting within the groups of Prof Molly Stevens (materials and bioengineering) and Dr Andrew Edwards (molecular microbiology) at ICL combines world-class expertise and provides an environment to maximise the success of this Fellowship, both in terms of the delivering the project and the training opportunities provided. Moreover, this innovative, alternative strategy to tackle drug-resistant Gram-negative bacterial infections has a high translational potential, which will be exploited via the clinical and translational research clinics at ICL.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BACDRUG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BACDRUG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

RegulatioNFkB (2019)

Deciphering transcriptional regulation of NF-kB target genes using integrative omics approaches

Read More